New pages
Jump to navigation
Jump to search
6 November 2026
- 12:3212:32, 6 November 2026 Autoimmune Encephalitis future or investigational therapies (hist | edit) [6,771 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis research is evaluating targeted immune treatments for patients with incomplete response to conventional therapy. Investigational treatment should be distinguished from established first- and second-line approaches. Published recommendations support specialist reassessment before rescue treatment because persistent disability does not necessarily...")
- 12:2812:28, 6 November 2026 Autoimmune Encephalitis cost-effectiveness of therapy (hist | edit) [5,863 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis can impose substantial hospital and long-term care costs. Published economic evidence includes resource-use studies and diagnostic-screening models, but these do not establish a universally most cost-effective immunotherapy.<ref name="Keller2026">Keller N, Bertram D, Hamer H, et al. [https://pubmed.ncbi.nlm.nih.gov/41998723/ Hospital resource use...")
- 12:1712:17, 6 November 2026 Autoimmune Encephalitis secondary prevention (hist | edit) [5,667 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis secondary prevention focuses on reducing relapse risk and recognizing recurrent disease after an initial episode. Follow-up and preventive treatment should reflect disease subtype, previous attacks, severity, and treatment risks. Long-term immunosuppression is not routinely recommended for every patient after a first presentation.<ref name="Hahn2...")
- 12:1212:12, 6 November 2026 Autoimmune Encephalitis primary prevention (hist | edit) [3,653 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis has no established disease-specific strategy that reliably prevents a first episode. Primary prevention concerns preventing disease before it develops; treatment of established encephalitis and prevention of relapse are separate issues. Expert information from Mayo Clinic emphasizes that consistent preventive measures for autoimmune causes of enc...")
- 12:0612:06, 6 November 2026 Autoimmune Encephalitis rehabilitation (hist | edit) [7,307 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis rehabilitation addresses physical, cognitive, communication, psychological, and participation difficulties after the acute illness. The 2024 Canadian consensus recommends screening for residual neuropsychiatric impairment and offering psychiatric care and neuropsychological rehabilitation when appropriate.<ref name="Hahn2024">Hahn C, Budhram A, A...")
- 11:5711:57, 6 November 2026 Autoimmune Encephalitis pediatric treatment considerations (hist | edit) [7,168 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis treatment in children requires pediatric neurology expertise, developmentally appropriate assessment, and individualized immunotherapy. The international pediatric treatment consensus specifically addresses N-methyl-D-aspartate receptor (NMDAR) antibody encephalitis; its recommendations should not automatically be applied to every childhood infla...")
- 07:4407:44, 6 November 2026 Autoimmune Encephalitis surgery (hist | edit) [6,914 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis is primarily treated medically, but removal of an associated tumor can be an important component of treatment. Surgery is directed at the relevant neoplasm or a specific complication, rather than routine removal of brain tissue.<ref name="Abboud2021">Abboud H, Probasco JC, Irani S, et al. [https://pubmed.ncbi.nlm.nih.gov/33649022/ Autoimmune ence...")
- 07:3307:33, 6 November 2026 Autoimmune Encephalitis interventions (hist | edit) [8,123 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis may require therapeutic plasma exchange and procedures to manage respiratory failure, severe autonomic dysfunction, nutritional difficulties, or refractory catatonia. Interventions are selected according to disease severity and complications and should accompany appropriate immunotherapy and treatment of an associated neoplasm.<ref name="AbboudAc...")
- 07:2507:25, 6 November 2026 Autoimmune Encephalitis symptomatic and supportive therapy (hist | edit) [7,011 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis requires symptomatic and supportive treatment alongside immunotherapy and treatment of an associated tumor. Care aims to control seizures and distress, prevent complications, and restore function. Symptomatic improvement alone does not establish that inflammation has resolved.<ref name="AbboudLong2021">Abboud H, Probasco J, Irani SR, et al. [http...")
- 07:0207:02, 6 November 2026 Autoimmune Encephalitis medical therapy (hist | edit) [6,452 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis is a potentially life-threatening, treatable neurological illness. Medical therapy combines early immunotherapy, treatment of an associated tumor when present, and management of seizures and systemic complications. Treatment depends on diagnostic confidence, disease severity, antibody subtype, comorbidities, and response.<ref name="Michael2026">M...")
5 November 2026
- 21:5021:50, 5 November 2026 Autoimmune Encephalitis pediatric considerations (hist | edit) [8,033 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis in children requires assessment of developmental change and age-specific presentations. N-methyl-D-aspartate receptor (NMDAR) antibody encephalitis is the most common recognized neuronal antibody-mediated subtype in childhood. Pediatric diagnostic recommendations complement adult criteria; they are provisional classification criteria rather than...")
- 21:4021:40, 5 November 2026 Autoimmune Encephalitis screening for an associated neoplasm (hist | edit) [8,589 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis may occur with an underlying neoplasm, including a benign ovarian teratoma. Screening seeks a potentially relevant tumor; it does not mean that every patient has cancer. The 2024 Canadian consensus recommends initial neoplasm screening in all adults presenting with autoimmune encephalitis, without waiting for neuronal antibody results.<re...")
- 21:2421:24, 5 November 2026 Autoimmune Encephalitis other diagnostic studies (hist | edit) [7,437 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== In autoimmune encephalitis, additional diagnostic studies are selected according to the clinical phenotype, unresolved differential diagnosis, and residual symptoms. They may characterize cognitive impairment, identify peripheral nerve involvement or sleep disorders, or investigate an alternative disease. No single additional study independently confirms or excludes autoimmune encephalitis.<re...")
- 21:0321:03, 5 November 2026 Autoimmune Encephalitis electroencephalography (hist | edit) [11,042 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== In autoimmune encephalitis, electroencephalography (EEG) helps identify seizures, nonconvulsive status epilepticus, and focal or generalized cerebral dysfunction. Common abnormalities include background slowing and epileptiform discharges, but these are not specific for an autoimmune cause. A normal EEG does not exclude autoimmune encephalitis.<ref name="Hahn2024">Hahn C, B...")
- 20:4020:40, 5 November 2026 Autoimmune Encephalitis other imaging findings (hist | edit) [6,547 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== In autoimmune encephalitis, additional imaging may support the neurological assessment or identify an associated tumor. Brain '''fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG PET)''' can be considered in selected diagnostically uncertain cases, including when magnetic resonance imaging (MRI) is normal or cannot be performed. An abnormal PET scan is not independently...")
- 20:0620:06, 5 November 2026 Autoimmune Encephalitis MRI (hist | edit) [10,562 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis may produce focal or multifocal abnormalities on magnetic resonance imaging (MRI), but a normal brain MRI does not exclude the disease. Imaging can support an inflammatory diagnosis, identify the anatomical pattern, and reveal alternative explanations for the presentation. Findings must be interpreted alongside the clinical course and other investigations.<ref name=...")
- 19:5419:54, 5 November 2026 Autoimmune Encephalitis CT (hist | edit) [5,736 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis has no specific diagnostic computed tomography (CT) appearance. Brain CT has limited sensitivity for autoimmune encephalitis, and a normal scan does not exclude the disease. In an acute presentation, head CT is principally useful for investigating alternative structural causes of symptoms or major intracranial complications.<ref name="Sanvito2024">Sanvito F, Pichiec...")
4 November 2026
- 15:2015:20, 4 November 2026 Autoimmune Encephalitis echocardiography or ultrasound (hist | edit) [8,035 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis has no characteristic echocardiographic or ultrasound finding that establishes the neurological diagnosis. Ultrasound is principally used to investigate associated tumors, particularly an ovarian teratoma in anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. Echocardiography is used selectively when cardiac disease is suspected, rather...")
- 13:5713:57, 4 November 2026 Autoimmune Encephalitis chest x ray (hist | edit) [5,186 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis has no characteristic chest X-ray finding, and chest radiography cannot establish or exclude the neurological diagnosis. Its role is to investigate associated thoracic disease or suspected respiratory complications when clinically indicated.<ref name="Abboud2021">Abboud H, Probasco JC, Irani S, et al. [https://jnnp.bmj.com/content/92/7/757 Autoimmune encephalitis: propo...")
- 13:4913:49, 4 November 2026 Autoimmune Encephalitis electrocardiogram (hist | edit) [8,459 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis has no diagnostic electrocardiogram (ECG) signature. ECG is useful for detecting associated cardiac rhythm disturbances and assessing medication-related cardiac effects. Autonomic dysfunction, especially in N-methyl-D-aspartate receptor (NMDAR) antibody encephalitis, may cause sinus tachycardia, bradycardia, sinus pauses, or se...")
- 13:2813:28, 4 November 2026 Autoimmune Encephalitis laboratory findings (hist | edit) [13,438 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Laboratory findings in autoimmune encephalitis may include inflammatory cerebrospinal fluid (CSF), evidence of intrathecal immunoglobulin G (IgG) synthesis, or a clinically relevant neural antibody. Routine blood and CSF results can be normal. No single routine laboratory pattern establishes or excludes every form of autoimmune encephalitis.<ref name="Hahn2024">{{cite journ...")
- 13:1713:17, 4 November 2026 Autoimmune Encephalitis physical examination (hist | edit) [10,823 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Physical examination in autoimmune encephalitis may reveal altered mental status, impaired memory, abnormal behavior, speech disturbance, seizures, or a movement disorder. Severe presentations may include reduced consciousness, autonomic instability, and respiratory compromise. Findings vary with the clinical syndrome, age, disease stage, and medication exposu...")
- 13:0713:07, 4 November 2026 Autoimmune Encephalitis history and symptoms (hist | edit) [11,445 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis symptoms include new memory difficulties, confusion, behavioral or psychiatric changes, and seizures. Speech disturbance, sleep disruption, unwanted movements, and reduced awareness may also occur. The combination and sequence vary between patients and antibody-associated subtypes.<ref name="Hahn2024">{{cite journal |author=Hahn C, Budhram A, Alikhani K, et al....")
- 12:5712:57, 4 November 2026 Autoimmune Encephalitis antibody-negative disease (hist | edit) [12,319 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Antibody-negative autoimmune encephalitis describes a clinically supported autoimmune encephalitis syndrome in which recognized neural antibodies have not been identified. The designation requires appropriate testing of serum and cerebrospinal fluid (CSF), objective assessment, and exclusion of competing diagnoses. '''A negative antibody panel alone does not establish autoimmune encephalitis.'''<r...")
3 November 2026
- 20:3720:37, 3 November 2026 Sandbox:AR (hist | edit) [87,171 bytes] Amna Riaz (talk | contribs) (Created page with "== Screening == Screening for pituitary adenomas is performed in three main clinical settings: # Individuals with a known or suspected germline predisposition to pituitary adenomas. # Patients with clinical features suggesting pituitary hormone excess. # Patients with an incidentally discovered sellar lesion. === 1. Individuals with a germline predisposition === ==== Indications for genetic evaluation ==== Genetic evaluation should be considered in patients with pit...")
2 November 2026
- 10:5110:51, 2 November 2026 Autoimmune Encephalitis clinical diagnostic criteria (hist | edit) [12,383 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis is classified as possible, probable, or definite according to the clinical syndrome and supporting evidence. The 2016 international criteria remain the basis of subsequent consensus guidance; these categories are not interchangeable.<ref name="Graus2016">{{cite journal |author=Graus F, Titulaer MJ, Balu R, et al. |title=A clinical approach to diagnosis of autoimmune encepha...")
1 November 2026
- 16:5016:50, 1 November 2026 Autoimmune Encephalitis diagnostic study of choice (hist | edit) [11,801 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis has '''no single universal diagnostic test or gold standard'''. Diagnosis combines clinical findings, cerebrospinal fluid (CSF) studies, neural antibodies, MRI, EEG, and exclusion of mimics.<ref name="Hahn2024">{{cite journal |author=Hahn C, Budhram A, Alikhani K, et al. |title=Canadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis in Adult...")
- 16:0516:05, 1 November 2026 Autoimmune Encephalitis natural history, complications and prognosis (hist | edit) [14,553 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis is potentially life-threatening, but substantial recovery is possible with appropriate treatment. The course varies with antibody subtype, associated neoplasm, attack severity, and treatment timing. Important complications include seizures, autonomic instability, respiratory compromise, and persistent cognitive or psychiatric impairment.<ref name="Hahn2024">{{cite journal |...")
- 14:4514:45, 1 November 2026 Autoimmune Encephalitis screening (hist | edit) [10,256 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis screening requires distinction between symptom-driven evaluation for encephalitis and investigation for an associated neoplasm. Current guidelines emphasize assessment of compatible clinical syndromes and appropriate tumor investigation; they do not establish a routine population-screening program for asymptomatic individuals.<ref name="Michael2026">{{cite journal |author=M...")
- 14:3314:33, 1 November 2026 Autoimmune Encephalitis risk factors (hist | edit) [10,084 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis comprises several immune-mediated brain disorders with different risk profiles. Recognized contexts include an associated tumor, previous herpes simplex encephalitis, immune checkpoint inhibitor exposure, and a background of autoimmunity. Age and sex associations depend on the antibody subtype. Many cases occur without an identified trigger.<ref name="Hahn2024">{{cite journ...")
- 13:4313:43, 1 November 2026 Autoimmune Encephalitis epidemiology and demographics (hist | edit) [13,621 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis is an uncommon group of immune-mediated brain disorders affecting children and adults. Epidemiological estimates depend on the antibody subtype, diagnostic criteria, population, and access to testing. Antibody-negative disease and differences in case ascertainment complicate comparisons between studies.<ref name="Hahn2024">{{cite journal |vauthors=Hahn C, Budhram A, Alikhan...")
- 13:1313:13, 1 November 2026 Autoimmune Encephalitis differential diagnosis (hist | edit) [20,688 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "{{CMG}} {{AE}} Julinka Auta Fernandes {{Autoimmune encephalitis}} '''To go back to the main page, click here.''' ==Overview== Autoimmune encephalitis must be differentiated from other diseases that cause subacute memory loss, altered mental status, psychiatric symptoms, seizures, and movement disorders. Important alternatives include infectious encephalitis, epilepsy, toxic-metabolic encephalopathy...")
- 12:1412:14, 1 November 2026 Autoimmune Encephalitis causes (hist | edit) [13,103 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} '''To go back to the main page, click here.''' ==Overview== Autoimmune encephalitis results from an immune response directed against components of the central nervous system. Its etiological contexts include disease with no identified precipitating trigger, tumor-associated autoimmunity, postinfectious autoimmunity, and iatrogenic autoimmunity, particularly following immune che...")
31 October 2026
- 17:0517:05, 31 October 2026 Autoimmune Encephalitis pathophysiology (hist | edit) [23,585 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "{{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis results from immune responses against neuronal antigens that disturb synaptic signaling, alter network excitability, and, in some forms, cause neuronal destruction. The relative contributions of antibodies, T cells, complement, and other inflammatory cells differ among syndromes.<ref name="Hahn2024">Hahn C, Budhram A, Alikhani K, et al. [https://doi.org/10....")
- 14:5514:55, 31 October 2026 Autoimmune Encephalitis classification (hist | edit) [19,638 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "{{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} '''To go back to the main page, click here.''' ==Overview== Autoimmune encephalitis may be classified according to antibody status and antigenic target, predominant clinical-anatomical syndrome, underlying cause, and diagnostic certainty. These classifications are complementary: a patient may simultaneously have an antibody-defined syndrome, a particular anatomica...")
- 14:3714:37, 31 October 2026 Autoimmune Encephalitis historical perspective (hist | edit) [19,380 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{JAF}} {{Autoimmune encephalitis}} ==Overview== Autoimmune encephalitis developed as a disease concept through successive clinical and immunological discoveries. Early descriptions of limbic encephalitis by Brierley and colleagues in 1960 and its association with carcinoma described by Corsellis and colleagues in 1968 established important foundations.<ref name="Brierley1960">Brierley JB, Cors...")
- 13:3713:37, 31 October 2026 Autoimmune Encephalitis (patient information) (hist | edit) [14,492 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with " __NOTOC__ {{Autoimmune encephalitis}} {{CMG}} {{AE}} {{JAF}} {| class="infobox bordered" style="width:15em; text-align:left; font-size:90%; background:AliceBlue;" |- ! style="text-align:center; background:LightSkyBlue;" | Autoimmune encephalitis<br />Patient information |- | Overview |- | Symptoms |- | Causes |- | #Who is at highest risk?|Who is at highest ri...")
- 12:5412:54, 31 October 2026 Autoimmune Encephalitis overview (hist | edit) [23,421 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "<!-- Page title: Autoimmune encephalitis overview. Sources checked: 31 October 2026. --> {{CMG}} '''Contributing editor:''' Julinka Auta Fernandes '''Synonyms and keywords:''' Autoimmune encephalitides; neuronal autoantibodies; limbic encephalitis; antibody-negative autoimmune encephalitis. __TOC__ ==Overview== Autoimmune encephalitis comprises immune-mediated inflammatory brain disorders that commonly cause evolving cognitive impa...")
30 October 2026
- 22:0322:03, 30 October 2026 Autoimmune Encephalitis (hist | edit) [3,563 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ '''For patient information click here''' {{CMG}} {{AE}} {{JAF}} {{SK}} Neuromyelitis optica spectrum disorder; NMOSD; neuromyelitis optica; NMO; Devic's disease; Devic's syndrome {{Neuromyelitis optica spectrum disorder}} == Overview == == Historical Perspective == == Neur...")
- 15:4815:48, 30 October 2026 Neuromyelitis optica spectrum disorder future or investigational therapies (hist | edit) [9,765 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{Neuromyelitis optica spectrum disorder}} {{CMG}} {{AE}} {{JAF}} ==Overview== Research on future and investigational therapies for neuromyelitis optica spectrum disorder (NMOSD) seeks to improve attack recovery, prevent relapses, and achieve more durable disease control. Important research directions include targeting antibody-producing cells, modifying antibody recycling, and immune reconstitution.<ref name="NEMOS20...")
- 14:4214:42, 30 October 2026 Neuromyelitis optica spectrum disorder cost-effectiveness of therapy (hist | edit) [7,224 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{Neuromyelitis optica spectrum disorder}} {{CMG}} {{AE}} {{JAF}} ==Overview== Cost-effectiveness of therapy for neuromyelitis optica spectrum disorder (NMOSD) depends on treatment costs, prevention of attacks, and the consequences of disability. A 2025 nationwide study illustrates why both medical expenditure and disability outcomes need consideration when evaluating treatment value.<ref name="Lee2025">{{cite journal...")
- 14:2914:29, 30 October 2026 Neuromyelitis optica spectrum disorder secondary prevention (hist | edit) [7,220 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{Neuromyelitis optica spectrum disorder}} {{CMG}} {{AE}} {{JAF}} ==Overview== Secondary prevention of neuromyelitis optica spectrum disorder (NMOSD) aims to prevent further inflammatory attacks and limit cumulative attack-related disability. Long-term immunotherapy is the cornerstone of this approach.<ref name="MENACTRIMS2026">{{cite journal |vauthors=Yamout B, Gouider R, Al-Roughani R |display-authors=etal |title...")
- 14:2014:20, 30 October 2026 Neuromyelitis optica spectrum disorder primary prevention (hist | edit) [1,954 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{Neuromyelitis optica spectrum disorder}} {{CMG}} {{AE}} {{JAF}} ==Overview== Primary prevention of neuromyelitis optica spectrum disorder (NMOSD) refers to preventing the initial development of the disease before its first clinical presentation. There is currently no established method for preventing NMOSD onset.<ref name="MedlinePlusNMOSD">{{cite web |title=Neuromyelitis optica spectrum disorder |website=MedlineP...")
- 14:1114:11, 30 October 2026 Neuromyelitis optica spectrum disorder Interventions (hist | edit) [8,529 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{Neuromyelitis optica spectrum disorder}} {{CMG}} {{AE}} {{JAF}} ==Overview== Interventions in neuromyelitis optica spectrum disorder (NMOSD) primarily involve therapeutic apheresis to treat acute inflammatory attacks. Prompt treatment and early escalation help limit permanent neurological disability.<ref name="MENACTRIMS2026">{{cite journal |vauthors=Yamout B, Gouider R, Al-Roughani R |display-authors=etal |title...")
- 13:5413:54, 30 October 2026 Neuromyelitis optica spectrum disorder surgery (hist | edit) [5,577 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{Neuromyelitis optica spectrum disorder}} {{CMG}} {{AE}} {{JAF}} ==Overview== Surgery has no established role in treating the underlying inflammation of neuromyelitis optica spectrum disorder (NMOSD). The mainstay of treatment is medical therapy for acute attacks and prevention of relapses.<ref name="NEMOS2024">{{cite journal |vauthors=Kümpfel T, Giglhuber K, Aktas O |display-authors=etal |title=Update on the dia...")
- 13:4013:40, 30 October 2026 Neuromyelitis optica spectrum disorder medical therapy (hist | edit) [10,923 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{Neuromyelitis optica spectrum disorder}} {{CMG}} {{AE}} {{JAF}} ==Overview== The mainstay of treatment for neuromyelitis optica spectrum disorder (NMOSD) is prompt treatment of acute attacks and long-term immunotherapy to prevent relapses. Treatment selection depends on aquaporin-4 immunoglobulin G (AQP4-IgG) antibody status, attack severity, comorbidities, reproductive plans, and treatment availability. The 2026 Mi...")
- 10:1910:19, 30 October 2026 Neuromyelitis optica spectrum disorder other diagnostic studies (hist | edit) [5,171 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{Neuromyelitis optica spectrum disorder}} {{CMG}} {{AE}} {{JAF}} ==Overview== Neuromyelitis optica spectrum disorder (NMOSD) is diagnosed by integrating clinical features, serum aquaporin-4 immunoglobulin G (AQP4-IgG) testing, magnetic resonance imaging (MRI), and exclusion of alternative diagnoses.<ref name="IPND2015">{{cite journal |vauthors=Wingerchuk DM, Banwell B, Bennett JL |display-authors=etal |title=Inter...")
- 10:0110:01, 30 October 2026 Neuromyelitis optica spectrum disorder other imaging findings (hist | edit) [4,519 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{Neuromyelitis optica spectrum disorder}} {{CMG}} {{AE}} {{JAF}} ==Overview== Neuromyelitis optica spectrum disorder (NMOSD) can be evaluated with optical coherence tomography (OCT) to assess retinal injury. The Neuromyelitis Optica Study Group (NEMOS) recommends OCT for supportive diagnostic information, although it is not formally required for diagnosis.<ref name="NEMOS2023">{{cite journal |vauthors=Jarius S,...")
- 09:5009:50, 30 October 2026 Neuromyelitis optica spectrum disorder echocardiography or ultrasound (hist | edit) [5,211 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{Neuromyelitis optica spectrum disorder}} {{CMG}} {{AE}} {{JAF}} ==Overview== Neuromyelitis optica spectrum disorder (NMOSD) has no established disease-specific echocardiographic or ultrasonographic diagnostic criteria. Diagnosis depends on the clinical presentation, serum aquaporin-4 immunoglobulin G (AQP4-IgG) antibody testing, magnetic resonance imaging (MRI), and exclusion...") Tag: Visual edit: Switched
29 October 2026
- 19:1819:18, 29 October 2026 Neuromyelitis optica spectrum disorder MRI (hist | edit) [14,255 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{Neuromyelitis optica spectrum disorder}} {{CMG}} {{AE}} {{JAF}} ==Overview== Magnetic resonance imaging (MRI) helps evaluate optic nerve, spinal cord, and brain involvement in neuromyelitis optica spectrum disorder (NMOSD). Findings must be interpreted together with the clinical presentation and antibody results.<ref name="IPND2015">{{cite journal |vauthors=Wingerchuk DM, Banwell B, Bennett JL |display-authors=etal...")